CÁNCER DE MAMA
![Foto de CÁNCER DE MAMA](/img/grupo.png)
![Foto de University of North Carolina at Chapel Hill](/img/noimage_org.png)
University of North Carolina at Chapel Hill
Chapel Hill, Estados UnidosPublicaciones en colaboración con investigadores/as de University of North Carolina at Chapel Hill (4)
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
2016
-
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89
2014
-
VAV3 mediates resistance to breast cancer endocrine therapy
Breast Cancer Research, Vol. 16, Núm. 3
2012
-
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
BMC Medical Genomics, Vol. 5